PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Genedata

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

UCB Expands Use of Genedata Software to Manage Biologics Lead Discovery Information - Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, announces an expansion of its research informatics collaboration with the global biopharmaceutical company UCB
UCB Expands Use of Genedata Software to Manage Biologics Lead Discovery Information

 

NewswireToday - /newswire/ - Basel, Switzerland, 2008/12/15 - Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, announces an expansion of its research informatics collaboration with the global biopharmaceutical company UCB.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The two companies have collaborated since 2006 with a focus on enhancing the management of drug target and biomarker discovery data using the Genedata Phylosopher® and Genedata Expressionist® platforms.

The collaboration has been renewed and expanded and now also supports UCB’s biologics and lead-finding activities in the fields of central nervous system disorders and autoimmune and inflammatory disorders research conducted in the UK and Belgium.

The extended collaboration aims to further expand the established platform from target discovery functionalities to lead generation support. For this advance, the Genedata Phylosopher platform is now additionally being used for storing proprietary drug candidate information produced by UCB’s biologics discovery efforts. As such, the Phylosopher database now relates therapeutic targets to protein-based drug leads, as well as sequence-based biologics reference data. This allows scientists to make better and faster drug discovery and development decisions.

In addition, Genedata Expressionist functionalities have been expanded to include data from much of UCB’s molecular profiling technology portfolio. Scientists can now review and explore multiple data types in one space to make better and faster decisions.

“Our decision to combine Genedata’s software products with our in-house customized software has been driven by the trust that we have developed in their established product line. This marriage has allowed us to leverage capabilities of both systems to support the generation of scientific insight more efficiently,” said Dr. Phil Scordis, UCB Senior Group Leader, Informatics. “We are pleased that we can work with Genedata as an experienced partner. It has been important to the progress of these activities that Genedata’s software products can be easily integrated into our existing infrastructure.”

“We are proud that we have been able to expand and diversify our relationship with UCB, a leading global biopharmaceutical company,” said Dr. Othmar Pfannes, CEO of Genedata. “Our collaboration with UCB is an excellent showcase of how Genedata’s products can meet a company’s specific needs for both small and large molecule drug discovery.”

About Genedata

Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Our solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.

About UCB

UCB, Brussels, Belgium (ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Genedata

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


UCB Expands Use of Genedata Software to Manage Biologics Lead Discovery Information

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Allison Kurz - Genedata.com 
+41 61 511 8459 communications[.]genedata.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Genedata securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Genedata / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)